Abstract submission form should be filled out and emailed to info@scadent.org. On-line Abstract Submission Deadline: August 15, 2012 (11:59 pm PST). No Paper Abstract Submissions will be accepted. Abstract Replacement Period Deadline: August 20, 2012 (11:59 pm PST)
You will be notified by email of provisional acceptance or rejection by September 1, 2012
The word limit for abstracts is 300 words. Presentation titles, names of authors and authors' affiliations are not included in the 300 word limit.
Each abstract must contain a brief statement of the objectives of the investigation, the experimental methods used, the important results including data summaries and, where appropriate, statistics, the conclusion of the work.
To achieve a more consistent style, the words: "Objectives:", "Methods:", "Results:", and "Conclusion:", each immediately followed by a colon as shown, must appear in the abstract.
In addition, all drugs and materials studied must be identified. Also, external funding must be specified by listing the name of supporting company or agency and, if appropriate, the grant number in the body of the abstract.
Presentations will be selected for the program on the basis of the quality of the work as judged from the abstract. Each abstract will be reviewed by reviewers with expertise in the aspects proposed for presentation.
Persons submitting an abstract for the General Session are doing so with the understanding that they must abide by the following policies